|

Azeliragon Clinical Trials

3 actively recruiting trials across 3 locations

▼ -1 trial since May 2026

Also known as: PF-04494700, TTP488

Pipeline

Early 1: 1Phase 1/2: 2

Top Sponsors

  • Washington University School of Medicine1
  • Cantex Pharmaceuticals1
  • Baptist Health South Florida1

Indications

  • Cancer3
  • Metastatic Pancreatic Cancer1
  • Metastasis1
  • Metastatic Cancer1
  • Brain Metastases, Adult1

Los Angeles, California1 trial

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

Phase 1/2

Miami, Florida1 trial

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

Miami Cancer Institute at Baptist Health, Inc.

Phase 1/2

St Louis, Missouri1 trial

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.